000 03232nam a22003855i 4500
001 393815
003 ES-MaUEC
005 20230102123030.0
007 cr nn 008mamaa
008 220825s2022 sz | s |||| 0|eng d
020 _a9783031121845
024 7 _a10.1007/978-3-031-12184-5
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
245 1 0 _aDisruptive Psychopharmacology
_cedited by Frederick S Barrett, Katrin H Preller
250 _a1st edition 2022
264 1 _aCham
_bSpringer International Publishing
_c2022
300 _a1 recurso en línea (VIII, 332 páginas)
_b100 ilustraciones, 30 ilustraciones a color
336 _atexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
490 0 _aCurrent Topics in Behavioral Neurosciences
_x1866-3389
_v56
505 0 _aDosing psychedelics and MDMA -- Psychedelic Group Therapy -- Set and Setting: Aesthetic experiences and their contribution to psychedelic therapies -- Psychedelic-Assisted Therapy for Social Adaptability in Autistic Adults -- Foundations for Training Psychedelic Therapists -- Ayahuasca for the Treatment of Depression -- Psilocybin for the Treatment of Depression -- Ketamine for the Treatment of Depression -- The Potential of Psychedelics for End of Life and Palliative Care -- Psychedelic-Assisted Therapy for Addiction and Potential Mechanisms of Action -- Psilocybin for Tobacco Use Disorder -- Psychedelic Drugs as Anti-Inflammatory Agents -- Psilocybin for the Treatment of Obsessive-Compulsive Disorder -- Psilocybin for the Treatment of Headache and Pain Disorders -- Psilocybin for the Treatment of Neurodegenerative Disorders -- Psilocybin for Trauma-Related Disorders.
520 _aPsychedelic therapies are gaining traction as potential treatments for a wide range of indications, but the structure and delivery of psychedelic therapies are a sharp departure from more traditional models of psychotherapy and pharmacotherapy for psychiatric and other medical disorders. This may be critical to their success. The current volume provides a comprehensive review of the state of the science of psychedelic therapies, including discussion of models and approaches to psychedelic therapies as well as the current status of safety and efficacy data for mood, substance use, trauma, obsessive-compulsive, neurodevelopmental, neurodegenerative disorders, neurological, and inflammatory disorders.
700 1 _aBarrett, Frederick S.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aPreller, Katrin H.
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
776 0 8 _iPrinted edition:
_z9783031121838
776 0 8 _iPrinted edition:
_z9783031121852
776 0 8 _iPrinted edition:
_z9783031121869
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-12184-5
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
988 _aSpringer_BiomedLife_2022
999 _c393815
_d393815